Table 1.
Patient demographics and baseline characteristics (treated set)
| Volasertib/cisplatin (n = 30) | Volasertib/carboplatin (n = 31) | |
|---|---|---|
| Age, median (range), years | 55 (17–77) | 58 (23–81) |
| Male/female, n (%) | 16 (53.3)/14 (46.7) | 18 (58.1)/13 (41.9) |
| Baseline ECOG PS, n (%) | ||
| 0 | 13 (43.3) | 14 (45.2) |
| 1 | 17 (56.7) | 17 (54.8) |
| Stage at diagnosis, n (%) | ||
| 0 | 0 (0.0) | 1 (3.2) |
| I | 1 (3.3) | 3 (9.7) |
| II | 1 (3.3) | 3 (9.7) |
| III | 9 (30.0) | 8 (25.8) |
| IV | 15 (50.0) | 15 (48.4) |
| Unknown | 4 (13.3) | 1 (3.2) |
| Type of cancer, n (%)a | ||
| NSCLC | 8 (26.7) | 6 (19.4) |
| CRC | 4 (13.3) | 4 (12.9) |
| Soft tissue sarcoma | 4 (13.3) | 4 (12.9) |
| Melanoma | 3 (10.0) | 0 (0.0) |
| Biliary tree | 2 (6.7) | 0 (0.0) |
| Bladder | 0 (0.0) | 3 (9.7) |
| Breast | 0 (0.0) | 2 (6.5) |
| Pleura | 0 (0.0) | 2 (6.5) |
| Any prior anticancer therapy, n (%) | ||
| Systemic chemotherapy | 28 (93.3) | 29 (93.5) |
| Surgery | 16 (53.3) | 19 (61.3) |
| Radiotherapy | 19 (63.3) | 15 (48.4) |
| Other | 14 (46.7) | 15 (48.4) |
Abbreviations: CRC colorectal cancer, ECOG PS Eastern Cooperative Oncology Group Performance Status, NSCLC non-small cell lung cancer
aIn >5 % of patients